Metabolic signatures in pancreatic ductal adenocarcinoma: diagnostic and therapeutic implications

被引:0
|
作者
Gong Ruining [1 ]
Hu Yonglu [8 ]
Yu Qian [1 ]
Fang Lin [11 ]
Ren He [1 ]
机构
[1] Phase I Clinical Research Center
[2] Shandong Provincial Key Laboratory of Clinical Research for Pancreatic Diseases
[3] Center for GI Cancer Diagnosis and Treatment  3. Tumor Immunology and Cytotherapy  4. Medical Research Center 
[4] Department of Endocrinology
[5] Qingdao  10. 266003
关键词
Diagnosis; Metabolism; Pancreatic ductal adenocarcinoma; Treatment; Tumor microenvironment;
D O I
暂无
中图分类号
R735.9 [胰腺肿瘤];
学科分类号
摘要
Pancreatic ductal adenocarcinoma (PDAC) is the prototypical aggressive cancer that develops in nutrient-deficient and hypoxic microenvironment. PDAC overcomes these restrictions by employing unconventional tactics for the procurement and usage of fuel sources. The substantial reprogramming of PDAC cell metabolism is driven by oncogene-mediated cell-autonomous pathways. PDAC cells use glucose, glutamine, and lipids for energy and depend on autophagy and macropinocytosis for survival and growth. They also interact metabolically with non-cancerous cells, aiding tumor progression. Many clinical trials focusing on altered metabolism are ongoing. Understanding the metabolic regulation of PDAC cells will not only help to increase understanding of the mechanisms of disease progression but also provide insights for the development of new diagnostic and therapeutic approaches.
引用
收藏
相关论文
共 50 条
  • [1] Metabolic signatures in pancreatic ductal adenocarcinoma: diagnostic and therapeutic implications
    Gong, Ruining
    Hu, Yonglu
    Yu, Qian
    Fang, Lin
    Ren, He
    JOURNAL OF PANCREATOLOGY, 2023, 6 (04) : 185 - 195
  • [2] Prognostic Metabolic Signatures in Pancreatic Ductal Adenocarcinoma (PDAC).
    Karasinska, Joanna
    Kalloger, Steve
    Wong, Hui-Li
    Renouf, Daniel
    Schaeffer, David
    MODERN PATHOLOGY, 2018, 31 : 680 - 680
  • [3] Prognostic Metabolic Signatures in Pancreatic Ductal Adenocarcinoma (PDAC).
    Karasinska, Joanna
    Kalloger, Steve
    Wong, Hui-Li
    Renouf, Daniel
    Schaeffer, David
    LABORATORY INVESTIGATION, 2018, 98 : 680 - 680
  • [4] New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma
    Mangge, Harald
    Niedrist, Tobias
    Renner, Wilfried
    Lyer, Stefan
    Alexiou, Christoph
    Haybaeck, Johannes
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (28) : 3012 - 3024
  • [5] MicroRNAs: Novel Diagnostic and Therapeutic Tools for Pancreatic Ductal Adenocarcinoma?
    Mardin, Wolf Arif
    Mees, Soeren Torge
    ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (11) : 3183 - 3189
  • [6] MicroRNAs: Novel Diagnostic and Therapeutic Tools for Pancreatic Ductal Adenocarcinoma?
    Wolf Arif Mardin
    Soeren Torge Mees
    Annals of Surgical Oncology, 2009, 16 : 3183 - 3189
  • [7] MicroRNAs in Pancreatic Ductal Adenocarcinoma: New Diagnostic and Therapeutic Clues
    Seux, Mylene
    Iovanna, Juan
    Dagorn, Jean-Charles
    Dusetti, Nelson J.
    PANCREATOLOGY, 2009, 9 (1-2) : 66 - 72
  • [8] Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma
    Rai, Vikrant
    Agrawal, Swati
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 24
  • [9] Diagnostic and Prognostic Performance of Metabolic Signatures in Pancreatic Ductal Adenocarcinoma: The Clinical Application of Quantitative NextGen Mass Spectrometry
    D'Amora, Paulo
    Silva, Ismael D. C. G.
    Evans, Steven S.
    Nagourney, Adam J.
    Kirby, Katharine A.
    Herrmann, Brett
    Cavalheiro, Daniela
    Francisco, Federico R.
    Bernard, Paula J.
    Nagourney, Robert A.
    METABOLITES, 2024, 14 (03)
  • [10] Exploring Molecular Signatures in Early-Stage Pancreatic Ductal Adenocarcinoma: Implications for Patient Management and Therapeutic Strategies
    Mousavi, S.
    Salehiazar, S.
    Baboli, K. Mirzaei
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 162 : S136 - S136